Risk factors for hospitalization and transfusion criteria in dengue patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a 3-year prospective observational study at a second-level hospital in northern Mexico that will enroll consecutive patients with laboratory-confirmed dengue who first present to the emergency department or outpatient clinic. Investigators will collect clinical data (fever duration, bleeding signs, vomiting, abdominal pain) and laboratory results (platelet count, hematocrit) along with detailed transfusion records. Patients will be followed from initial presentation until clinical resolution or hospital discharge. Multivariate logistic regression will be used to identify independent predictors of hospitalization and transfusion and to describe real-world transfusion practices and outcomes in this setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥5 years
* Laboratory-confirmed dengue infection (NS1, IgM, or PCR)
* First contact at emergency or outpatient services
* Informed consent signed by the patient or legal guardian

Exclusion Criteria:

* Co-infection with other arboviruses or COVID-19
* Pre-existing hematologic or oncologic disease
* Refusal to sign informed consent

Where it's running

• Clinica Mexico
  Piedras Negras, Coahuila, Mexico Recruiting

Study contacts

• Study coordinator: JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, MD, MSc, Ph, Specialist
• Email: jefe.urgencias@clinicamexico.com
• Phone: 525525848735

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry of dengue infection in people with congenital bleeding disorders

  This registry will collect information to see how dengue affects people with congenital bleeding disorders, such as hemophilia and von Willebrand disease, and what treatments and outcomes occur.

  Recruiting Mahidol University · Bangkok · NCT07409857

• Dengue virus challenge in healthy adults to study immune responses

  Researchers will infect healthy adults with a weakened dengue virus to see how their bodies respond and how past exposure affects the reaction.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07706686

• Gut leakage in dengue: is the intestinal barrier affected during infection?

  Researchers are studying whether dengue infection disrupts the gut barrier and if that contributes to severe disease in adults with dengue who are in hospital.

  Recruiting University of Oxford · Chittagong, Chattogram Division · NCT07602920

• CP-COV03 versus placebo for adults with dengue or dengue-like illness

  This trial tests whether taking CP-COV03 for seven days helps adults with dengue (or dengue-like illnesses) recover faster and lower their viral levels compared with a placebo.

  Recruiting at 2 sites Phase 2/3 Hyundai Bioscience Co., Ltd. · Hanoi and 1 other locations · NCT07576868

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Immune responses in dengue and sepsis

  This project will collect blood from people hospitalized with dengue-like illness or sepsis and from healthy volunteers to see how their immune responses change over time.

  Recruiting at 4 sites Institut Pasteur du Cambodge · Kampong Speu and 3 other locations · NCT07040202

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.